Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARI-0001 |
Synonyms | |
Therapy Description |
ARI-0001 are autologous T-lymphocytes engineered to express a CD137-based chimeric antigen receptor (CAR) targeting CD19, which may have antitumor activity (PMID: 35174095). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARI-0001 | ARI0001|ARI 0001|PEI 19-187 | CD19 Immune Cell Therapy 62 | ARI-0001 are autologous T-lymphocytes engineered to express a CD137-based chimeric antigen receptor (CAR) targeting CD19, which may have antitumor activity (PMID: 35174095). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04778579 | Phase II | ARI-0001 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy (CART19-BE-02) | Active, not recruiting | ESP | 0 |
NCT05641428 | Phase II | axicabtagene ciloleucel ARI-0001 | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) | Recruiting | NLD | 0 |